Expert Insights on NSCLC: Unmet Needs and Innovations from ASCO 2024

Jason Porter, MD, outlines the most significant unaddressed challenges in treating and managing non-small cell lung cancer as the field approaches the American Society of Clinical Oncology's 2024 annual meeting.

Now Viewing

EP: 1.Expert Insights on NSCLC: Unmet Needs and Innovations from ASCO 2024

EP: 2.ASCO 2024: Key Findings of the LAURA Trial on Osimertinib for EGFR-Mutated NSCLC

EP: 3.Evaluating Amivantamab and Lazertinib: Key Findings from the CHRYSALIS-2 Study at ASCO 2024

EP: 4.Insights from the TROPION-Lung05 Trial at ASCO 2024

EP: 5.Long-Term Follow-Up from CheckMate 9LA at ASCO 2024

EP: 6.ASCO 2024 and Beyond: Addressing NSCLC Unmet Needs and Future Research Directions

Related Videos

Related Content

Advertisement

July 8th 2025

Severe COVID-19 Linked to Higher Exacerbation, Mortality Risks in Patients With Bronchiectasis

Brooke McCormick

Patients with bronchiectasis face heightened risks of severe exacerbation and mortality after COVID-19 recovery, especially following severe cases.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 8th 2025

Corticosteroid Premedication for Infliximab Remains Unnecessarily Common

Shirley Cohen-Mekelburg, MD, MS Jeffrey Gibbs, MD Beth Wallace, MD, MS Brooke Kenney, MPH Akbar K. Waljee, MD, MSc

Although use of corticosteroid premedication prior to infliximab infusions is declining, it remains unnecessarily high despite limited benefit and the risk of serious adverse events from corticosteroids.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

July 7th 2025

Cases Show How Epcoritamab Revived CAR T Cells After Relapse in DLBCL

Mary Caffrey

July 7th 2025

The Rise of Precision Monoclonal Antibodies in Treating MS

Skylar Jeremias

Advancements in B-cell therapies, including anti-CD20 and anti-CD19 monoclonal antibodies, enhance treatment efficacy and safety for multiple sclerosis and autoimmune diseases.

Related Content

Advertisement

July 8th 2025

Severe COVID-19 Linked to Higher Exacerbation, Mortality Risks in Patients With Bronchiectasis

Brooke McCormick

Patients with bronchiectasis face heightened risks of severe exacerbation and mortality after COVID-19 recovery, especially following severe cases.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 8th 2025

Corticosteroid Premedication for Infliximab Remains Unnecessarily Common

Shirley Cohen-Mekelburg, MD, MS Jeffrey Gibbs, MD Beth Wallace, MD, MS Brooke Kenney, MPH Akbar K. Waljee, MD, MSc

Although use of corticosteroid premedication prior to infliximab infusions is declining, it remains unnecessarily high despite limited benefit and the risk of serious adverse events from corticosteroids.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

July 7th 2025

Cases Show How Epcoritamab Revived CAR T Cells After Relapse in DLBCL

Mary Caffrey

July 7th 2025

The Rise of Precision Monoclonal Antibodies in Treating MS

Skylar Jeremias

Advancements in B-cell therapies, including anti-CD20 and anti-CD19 monoclonal antibodies, enhance treatment efficacy and safety for multiple sclerosis and autoimmune diseases.